COVID-19 IgM/IgG Rapid Test Approved by INVIMA in Colombia!
We are excited to announce that the National Institute for Food and Drug Surveillance (INVIMA) has given BioMedomics, Inc. authorization to sell and distribute our
Early Diagnosis
Saves Lifes
Easy to use, affordable, accurate, advanced
diagnostic tests for everyone
What We Do
At BioMedomics, we use cutting-edge technology to create life saving diagnostic solutions and address global healthcare needs. BioMedomics is an ISO 13485 certified company based out of Research Triangle Park, North Carolina. Our diagnostic tests produce rapid and accurate clinical results at the point-of-care without requiring complex and expensive lab equipment-placing immediate healthcare knowledge in the hands of providers. With that knowledge comes the power to make treatment decisions and save lives.
Why We're Needed
Despite treatment availability, people in rural and remote communities still die from easily treatable diseases due to limited diagnostic testing capabilities. Mortality rates for some diseases severely affects under-resourced countries, which may lack the infrastructure to transport expensive laboratory equipment, recruit trained personnel, and supply reliable electricity. It’s a void that point-of-care diagnostic tests are designed to fill. Our diagnostic tests can be used anywhere, anytime, making it possible to provide simple, quick, accurate, and affordable clinical results to the most vulnerable members of society.
Our Solution
Products
We make point-of-care diagnostic tests which provide immediate answers to individuals and their healthcare providers wherever they are. Our innovative products are dedicated to the diagnosis of blood disorders and the identification of microorganisms and pathogens of global concern. Explore our product pages for more information.
Research & Development
BioMedomics is committed to meeting unmet market needs by developing innovative point-of-care diagnostic technologies. We are working on ways to harness antibody design and development, advanced immunoassay platforms, and testing automation and A.I. for applications in hematology, infectious disease, oncology, women’s health, and other areas.
Latest News
Sickle SCAN® Approved by Department of Health in Australia!
We are excited to announce that the Therapeutic Goods Administration, a branch of the Department of Health in the Australian Government, has given BioMedomics, Inc.
Sickle SCAN® Approved by the Tanzania Medicines and Medical Devices Authority!
We are excited to announce that the Tanzania Medicines and Medical Devices Authority has given authorization to BioMedomics, Inc. to sell and distribute our world-renown